Impact of glucocorticoids on the therapeutic efficacy of denosumab against osteoporosis in patients with rheumatoid arthritis

Background: Rheumatoid arthritis (RA) and prolonged high-dose glucocorticoid (GC) treatment are established risk factors for osteoporosis. Objectives: In this study, we aimed to evaluate the therapeutic efficacy of denosumab according to the GC dose considered to increase the risk of glucocorticoid-...

Full description

Saved in:
Bibliographic Details
Main Authors: Jiwon Yang, Youngjae Park, Jennifer Jooha Lee, Seung-Ki Kwok, Ji Hyeon Ju, Wan-Uk Kim, Sung-Hwan Park
Format: Article
Language:English
Published: SAGE Publishing 2025-01-01
Series:Therapeutic Advances in Musculoskeletal Disease
Online Access:https://doi.org/10.1177/1759720X251314712
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832582833095311360
author Jiwon Yang
Youngjae Park
Jennifer Jooha Lee
Seung-Ki Kwok
Ji Hyeon Ju
Wan-Uk Kim
Sung-Hwan Park
author_facet Jiwon Yang
Youngjae Park
Jennifer Jooha Lee
Seung-Ki Kwok
Ji Hyeon Ju
Wan-Uk Kim
Sung-Hwan Park
author_sort Jiwon Yang
collection DOAJ
description Background: Rheumatoid arthritis (RA) and prolonged high-dose glucocorticoid (GC) treatment are established risk factors for osteoporosis. Objectives: In this study, we aimed to evaluate the therapeutic efficacy of denosumab according to the GC dose considered to increase the risk of glucocorticoid-induced osteoporosis (GIOP) in patients with RA. Design: A retrospective analysis of collected data on RA patients with osteoporosis starting denosumab. Methods: We included 418 patients with RA who were started on denosumab therapy and categorized them into those with and without GC intake ⩾2.5 mg/day for >3 months. The T -score and areal bone mineral density (aBMD) at the lumbar spine, total hip, and femur neck, as well as serum bone turnover markers, were measured at baseline and 12 months. We performed between-group and within-group comparisons of the BMD values at baseline and at 12 months. Results: Denosumab significantly increased the T -scores and aBMD at the lumbar spine, total hip, and femur neck after 12 months, regardless of GC intake. However, apart from the T -score at the lumbar spine, the other parameters did not show significant between-group differences. Similarly, in patients with anti-cyclic citrullinated peptide (CCP) antibody positivity or those treated with biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs), although there were significant increases in the T -score and areal BMD at all sites in both groups, there were no significant between-group differences. Conclusion: Our findings suggest that the GC dose considered to increase the risk of GIOP did not significantly attenuate the therapeutic efficacy of denosumab in RA patients, including those positive for anti-CCP antibodies and users of biologic or targeted synthetic DMARDs.
format Article
id doaj-art-ce5f685d690440a69d6b139dc79f4655
institution Kabale University
issn 1759-7218
language English
publishDate 2025-01-01
publisher SAGE Publishing
record_format Article
series Therapeutic Advances in Musculoskeletal Disease
spelling doaj-art-ce5f685d690440a69d6b139dc79f46552025-01-29T09:03:58ZengSAGE PublishingTherapeutic Advances in Musculoskeletal Disease1759-72182025-01-011710.1177/1759720X251314712Impact of glucocorticoids on the therapeutic efficacy of denosumab against osteoporosis in patients with rheumatoid arthritisJiwon YangYoungjae ParkJennifer Jooha LeeSeung-Ki KwokJi Hyeon JuWan-Uk KimSung-Hwan ParkBackground: Rheumatoid arthritis (RA) and prolonged high-dose glucocorticoid (GC) treatment are established risk factors for osteoporosis. Objectives: In this study, we aimed to evaluate the therapeutic efficacy of denosumab according to the GC dose considered to increase the risk of glucocorticoid-induced osteoporosis (GIOP) in patients with RA. Design: A retrospective analysis of collected data on RA patients with osteoporosis starting denosumab. Methods: We included 418 patients with RA who were started on denosumab therapy and categorized them into those with and without GC intake ⩾2.5 mg/day for >3 months. The T -score and areal bone mineral density (aBMD) at the lumbar spine, total hip, and femur neck, as well as serum bone turnover markers, were measured at baseline and 12 months. We performed between-group and within-group comparisons of the BMD values at baseline and at 12 months. Results: Denosumab significantly increased the T -scores and aBMD at the lumbar spine, total hip, and femur neck after 12 months, regardless of GC intake. However, apart from the T -score at the lumbar spine, the other parameters did not show significant between-group differences. Similarly, in patients with anti-cyclic citrullinated peptide (CCP) antibody positivity or those treated with biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs), although there were significant increases in the T -score and areal BMD at all sites in both groups, there were no significant between-group differences. Conclusion: Our findings suggest that the GC dose considered to increase the risk of GIOP did not significantly attenuate the therapeutic efficacy of denosumab in RA patients, including those positive for anti-CCP antibodies and users of biologic or targeted synthetic DMARDs.https://doi.org/10.1177/1759720X251314712
spellingShingle Jiwon Yang
Youngjae Park
Jennifer Jooha Lee
Seung-Ki Kwok
Ji Hyeon Ju
Wan-Uk Kim
Sung-Hwan Park
Impact of glucocorticoids on the therapeutic efficacy of denosumab against osteoporosis in patients with rheumatoid arthritis
Therapeutic Advances in Musculoskeletal Disease
title Impact of glucocorticoids on the therapeutic efficacy of denosumab against osteoporosis in patients with rheumatoid arthritis
title_full Impact of glucocorticoids on the therapeutic efficacy of denosumab against osteoporosis in patients with rheumatoid arthritis
title_fullStr Impact of glucocorticoids on the therapeutic efficacy of denosumab against osteoporosis in patients with rheumatoid arthritis
title_full_unstemmed Impact of glucocorticoids on the therapeutic efficacy of denosumab against osteoporosis in patients with rheumatoid arthritis
title_short Impact of glucocorticoids on the therapeutic efficacy of denosumab against osteoporosis in patients with rheumatoid arthritis
title_sort impact of glucocorticoids on the therapeutic efficacy of denosumab against osteoporosis in patients with rheumatoid arthritis
url https://doi.org/10.1177/1759720X251314712
work_keys_str_mv AT jiwonyang impactofglucocorticoidsonthetherapeuticefficacyofdenosumabagainstosteoporosisinpatientswithrheumatoidarthritis
AT youngjaepark impactofglucocorticoidsonthetherapeuticefficacyofdenosumabagainstosteoporosisinpatientswithrheumatoidarthritis
AT jenniferjoohalee impactofglucocorticoidsonthetherapeuticefficacyofdenosumabagainstosteoporosisinpatientswithrheumatoidarthritis
AT seungkikwok impactofglucocorticoidsonthetherapeuticefficacyofdenosumabagainstosteoporosisinpatientswithrheumatoidarthritis
AT jihyeonju impactofglucocorticoidsonthetherapeuticefficacyofdenosumabagainstosteoporosisinpatientswithrheumatoidarthritis
AT wanukkim impactofglucocorticoidsonthetherapeuticefficacyofdenosumabagainstosteoporosisinpatientswithrheumatoidarthritis
AT sunghwanpark impactofglucocorticoidsonthetherapeuticefficacyofdenosumabagainstosteoporosisinpatientswithrheumatoidarthritis